GEN 003

Drug Profile

GEN 003

Alternative Names: GEN-003; Herpes simplex virus type 2 therapeutic vaccine - Genocea Biosciences; HSV-2 Tx - Genocea Biosciences; HSV-2 vaccine - Genocea Biosciences

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genocea Biosciences
  • Class Antivirals; Immunotherapies; Subunit vaccines; Viral vaccines
  • Mechanism of Action B cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes simplex virus type 2 infections

Most Recent Events

  • 24 Jul 2017 Efficacy and adverse events data from a phase IIb trial in Herpes simplex virus type-2 infections released by Genocea Biosciences
  • 25 May 2017 Genocea Biosciences completes a phase IIb trial in Herpes simplex virus type-2 infections in USA (NCT02515175)
  • 24 May 2017 Genocea Biosciences initiates a phase II maintenance dose trial for Herpes simplex virus type-2 infections (In children, In adults, In the elderly) (IM) (NCT03146403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top